{"id":"NCT05270863","sponsor":"Visus Therapeutics","briefTitle":"Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia","officialTitle":"Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-30","primaryCompletion":"2023-03-17","completion":"2023-04-10","firstPosted":"2022-03-08","resultsPosted":"2024-09-05","lastUpdate":"2024-10-15"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"DRUG","name":"BRIMOCHOL™ PF","otherNames":["carbachol/brimonidine tartrate"]},{"type":"DRUG","name":"Carbachol PF","otherNames":["carbachol monotherapy"]},{"type":"DRUG","name":"Brimonidine tartrate","otherNames":["brimonidine tartrate monotherapy"]}],"arms":[{"label":"BRIMOCHOL™ PF","type":"EXPERIMENTAL"},{"label":"Carbachol PF","type":"ACTIVE_COMPARATOR"},{"label":"Brimonidine tartrate","type":"ACTIVE_COMPARATOR"}],"summary":"Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","primaryOutcome":{"measure":"Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity","timeFrame":"Day 1 Hour 1","effectByArm":[{"arm":"BRIMOCHOL™ PF","deltaMin":49.4,"sd":null},{"arm":"Carbachol PF","deltaMin":35,"sd":null},{"arm":"Brimonidine Tartrate","deltaMin":22.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<.001"}]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":178},"commonTop":["Eye Irritation","Headache"]}}